A human papillomavirus vaccine.
A recombinant quadrivalent human-papillomavirus-like particle vaccine, Gardasil (Merck), has been approved by the FDA for use in girls and women 9-26 years old to prevent diseases associated with infection with human papillomavirus (HPV) types 6, 11, 16, and 18, including genital warts, precancerous cervical, vaginal or vulvar lesions, and cervical cancer.
D000293:Adolescent; D000328:Adult; D002648:Child; D003218:Condylomata Acuminata / Q000517:prevention & control*; D015344:DNA Probes, HPV; D017277:Drug Approval; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D052140:Human papillomavirus 11; D052162:Human papillomavirus 16; D052163:Human papillomavirus 6; D006801:Humans; D032541:Mass Vaccination; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D011230:Precancerous Conditions / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects
D015344:DNA Probes, HPV; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; D014765:Viral Vaccines